Brendan Veeneman

Brendan Veeneman currently serves as the Director of Computational Biology at Delphia Therapeutics since March 2024. Prior to this role, Brendan held the position of Associate Director in Oncology Data and Analytical Strategy at GSK from October 2020 to March 2024, where duties included directing a target discovery portfolio and leading validation programs. Brendan also worked as a Senior Computational Biologist at Pfizer from April 2017 to September 2020, focusing on discovering oncology drug targets through CRISPR/Cas9 screen analysis. Earlier in Brendan's career, a Senior Scientist role at the University of Michigan involved extensive tumor analysis using innovative cloud-based methods, while Brendan contributed to bioinformatics advancements as a PhD student and Bioinformatics Scientist at Febit Inc. Brendan holds a Ph.D. in Bioinformatics from the University of Michigan and a Bachelor of Arts in Biology with a Computer Science minor from Oberlin College.